SM
VVOS icon

Sabby Management’s Vivos Therapeutics VVOS Stock Holding History

Sabby Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,502
Closed -$53.5K – 48
2024
Q3 		$53.5K Buy
+20,502
New +$53.7K 0.03% 27

Other funds holding VVOS

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sabby Management's VVOS Position: Q4 2024 in Review

Sabby Management sold out of Vivos Therapeutics (VVOS) in Q4 2024, closing a stake of 20,502 shares — an estimated $53.5K sold.

Sabby Management first reported a position in VVOS in Q3 2024 and held it in 1 quarter. The position peaked at $53.5K in Q3 2024. 20 funds tracked by Wall St. Rank hold VVOS as of Q4 2024.

  • Sabby Management reported no remaining Vivos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sabby Management sold 20,502 Vivos Therapeutics shares in Q4 2024, an estimated $53.5K.
  • Sabby Management first reported a position in Vivos Therapeutics in Q3 2024 and held it in 1 quarter.
  • Sabby Management's Vivos Therapeutics position peaked at $53.5K in Q3 2024.
  • 20 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2024.

Based on Sabby Management's 13F filing for Q4 2024, filed 14 Feb 2025.